Antifungal prophylaxis during neutropenia and immunodeficiency

Clinical Microbiology Reviews

Volumn 10, Issue 3, 1997, Pages 477-504

  Lortholary, Olivier ^a,b   Dupont, Bertrand ^b  

^a UNIVERSITÉ PARIS 13   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; CYTOKINE; FLUCONAZOLE; HEMOPOIETIC GROWTH FACTOR; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN;

ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; CELL FUNCTION; CONNECTIVE TISSUE; CRYPTOCOCCUS NEOFORMANS; DRUG COST; DRUG EFFICACY; DRUG INTERACTION; GEOGRAPHIC DISTRIBUTION; GRAFT REJECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PROPHYLAXIS; REVIEW; SURVIVAL; TOPICAL DRUG ADMINISTRATION;

ASPERGILLUS; CANDIDA; FILOBASIDIELLA NEOFORMANS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030849193     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.10.3.477     Document Type: Review

References (390)

1. Abi-Said, D., and E. J. Anaissie. 1995. New emerging fungal pathogens, p. 71-87. In F. Meunier (ed.), Invasive fungal infections in cancer patients. Baillière Tindall, London, United Kingdom.
2. Agresti, M. G., F. De Bernardis, F. Mondello, R. Bellocco, G. P. Carosi, R. M. Caputo, F. Milazzo, F. Chiodo, V. Giannini, L. Minoli, L. Ortona, G. Pastore, M. Piazza, G. Scalise, A. Cirelli, A. Chiesi, D. Greco, S. Vella, and A. Cassonne. 1994. Clinical and mycological evaluation of fluconazole in the secondary prophylaxis of esophageal candidiasis in AIDS patients. An open, multicenter study. Eur. J. Epidemiol. 10:17-22.
3. Aisner, J., J. Murillo, S. C. Schimpff, and A. C. Steeve. 1979. Invasive aspergillosis in acute leukemia: correlation with nose cultures and antibiotic use. Ann. Intern. Med. 90:4-9.
4. Akiyama, H., S. Mori, S. Tanikawa, H. Sakamaki, and Y. Onozawa. 1993. Fluconazole versus oral amphotericin B in preventing fungal infection in chemotherapy-induced neutropenic patients with haematological malignancies. Mycoses 36:373-378.
5. Akova, M., H. E. Akalin, O. Uzun, and D. Gür. 1991. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur. J. Clin. Microbiol. Infect. Dis. 10:598-599.
6. Alangaden, G., P. H. Chandrasekar, E. Bailey, Y. Khaliq, and the Bone Marrow Transplantation Team. 1994. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplant. 14:919-924.
7. Allen, S. D., K. N. Sorensen, M. J. Nejdl, C. Durrant, and R. T. Proffit. 1994. Prophylactic efficacy of aerosolized liposomal (AmBisome) and nonliposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J. Antimicrob. Chemother. 34:1001-1013.
8. Allison, R. R., V. Vongtama, J. Vaughan, and K. H. Shin. 1995. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole. Cancer Invest. 13:16-22.
9. Ammassari, A., A. Linzalone, R. Murri, G. Marasca, G. Morace, and A. Antinori. 1995. Fluconazole for primary prophylaxis of AIDS-associated cryptococcosis: a case-control study. Scand. J. Infect. Dis. 27:235-237.
10. Ampel, N. M. 1996. Emerging disease issues and fungal pathogens associated with HIV infection. Emerging Infect. Dis. 2:109-116.
11. Anaissie, E. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 14(Suppl. 1): S43-S53.
12. Anaissie, E., G. P. Bodey, H. Kantarjian, C. David, K. Barnett, E. Bow, R. Defelice, N. Downs, T. File, G. Karam, D. Potts, M. Shelton, and A. Sugar. 1991. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am. J. Med. 91:142-150.
13. Anaissie, E., G. P. Bodey, H. Kantarjian, J. Ro, S. E. Vartivarian, R. Hopfer, J. Hoy, and K. Rolston. 1989. New spectrum of fungal infections in patients with cancer. Rev. Infect. Dis. 2:369-378.
14. Anaissie, E., V. Fainstein, T. Samo, G. P. Bodey, and G. A. Sarosi. 1988. Central nervous system histoplasmosis: an unappreciated complication of the acquired immunodeficiency syndrome. Am. J. Med. 84:215-217.
15. Annaloro, C., A. Oriani, E. Tagliaferri, V. Bertolli, A. D. Volpe, D. Soligo, A. Ibatici, E. Pozzoli, and G. L. Deliliers. 1995. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 80:512-517.
16. Barchiesi, F., A. L. Colombo, D. A. McGough, A. W. Fothergill, and M. G. Rinaldi. 1994. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 38:1530-1533.
17. Barrett, A. P. 1984. Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immuno-suppressed patients. Oral Surg. Oral Med. Oral Pathol. 58:148-151.
18. Bartizal, K., G. Abruzzo, C. Trainor, D. Krupa, K. Nollstadt, D. Schmatz, R. Schartz, M. Hammond, J. Balkovec, and F. Vanmiddlesworht. 1992. In vitro antifungal activities and in vivo efficacies of 1,3-β-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob. Agents Chemother. 36:1648-1657.
19. Behre, G. F., S. Schwartz, K. Lenz, W. D. Ludwig, E. Schilling, V. Heinemann, H. Link, O. Boenisch, W. Treder, W. Siegert, H. Wandt, A. Trittin, W. Hiddemann, and J. Beyer. 1995. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann. Hematol. 71:287-291.
20. Benedetti, E., A. C. Gruessner, C. Troppman, B. E. Papalois, D. E. R. Sutherland, D. L. Dunn, and R. W. G. Gruessner. 1996. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J. Am. Coll. Surg. 183:307-316.
21. Benhamou, E., O. Hartmann, C. Nogues, D. Maraninchi, D. Valteau, and J. Lemerle. 1991. Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial. Bone Marrow Transplant. 7:127-131.
22. Bensinger, W. I., T. H. Price, D. C. Dale, F. R. Appelbaum, R. Clift, K. Lilleby, B. Williams, R. Storb, E. D. Thomas, and C. D. Buckner. 1993. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81:1883-1886.
23. Berkowitz, R. J., C. Hughes, M. Rudnick, E. M. Gordon, S. Strandjord, N. K. Cheung, P. Warkentin, and P. F. Coccia. 1985. Oropharyngeal Candida prophylaxis in pediatric bone marrow transplant patients. Am. J. Pediatr. Hematol. Oncol. 7:82-86.
24. Bernhisel-Broadbent, J., E. E. Camargo, H. S. Jaffe, and H. M. Lederman. 1991. Recombinant human interferon-gamma as adjunct therapy for aspergillus infection in a patient with chronic granulomatous disease. J. Infect. Dis. 163:908-911.
25. Beyer, J., G. Barzen, G. Risse, C. Weyer, K. Miksits, K. Dullenkopf, D. Huhn, and W. Siegert. 1993. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 37:1367-1369.
26. Beyer, J., S. Schwartz, V. Heinemann, and W. Siegent. 1994. Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrob. Agents Chemother. 38:911-917.
27. Bodey, G. P., B. Bueltmann, W. Duguid, D. Gibbs, H. Hanak, M. Hotchi, G. Mall, P. Martino, F. Meunier, S. Milliken, S. Naoe, M. Okudaira, D. Scevola, and J. van't Wout. 1992. Fungal infections in cancer patients: an international autopsy survey. Eur. J. Clin. Microbiol. 11:99-109.
28. Bodey, G. P. 1966. Fungal infections complicating acute leukemia. J. Chronic Dis. 19:667-687.
29. Bodey, G. P., E. Anaissie, J. Gutterman, and S. Badhan Raj. 1993. Role of granulocyte macrophage colony stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin. Infect. Dis. 17:705-707.
30. Bodey, G. P., E. J. Anaissie, L. S. Elting, E. Estey, S. O'Brien, and H. Kantarjian. 1994. Antifungal prophylaxis during remission, induction therapy for acute leukemia, fluconazole versus intravenous amphotericin B. Cancer 73:2099-2106.
31. Boelaert, J. R., J. Van Cutsen, M. de Locht, Y. J. Schneiden, and R. R. Crichton. 1994. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effects. Kidney Int. 45: 667-671.
32. Boogaerts, M. A., G. E. Verhoef, P. Zachee, H. Demuynck, L. Verbist, and K. De Beule. 1989. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 32(Suppl. 1):103-108.
33. Bozzette, S. A., R. A. Larsen, J. Chiu, M. A. E. Leal, J. Jacobsen, P. Rothman, P. Robinson, G. Gilbert, J. A. McCutchan, J. Tilles, J. M. Leedom, and D. D. Richman. 1991. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N. Engl. J. Med. 324:580-584.
34. Brajtburg, J., and J. Bolard. 1996. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9:512-531.
35. Brammer, K. W. 1990. Management of fungal infection in neutropenic patients with fluconazole. Haematol.-Bluttransfus. 33:546-550.
36. Brammer, K. W., P. R. Farrow, and J. K. Faulkner. 1990. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis 12(Suppl. 3):318-326.
37. Briegel, J., H. Forst, B. Spill, A. Haas, B. Grabein, M. Haller, E. Kilger, K. W. Jauch, K. Maag, G. Ruckdeschel, and K. Peter. 1995. Risk factors for systemic fungal infections in liver transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 14:375-382.
38. Brincker, H. 1978. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection: a placebo-controlled double-blind study. Acta Med. Scand. 204:123-128.
39. Brincker, H. 1983. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment. Mykosen 26:242-247.
40. Bross, J., G. H. Talbot, G. Maislin, S. Hurwitz, and B. L. Strom. 1989. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am. J. Med. 87:614-620.
41. Brummer, E., and D. A. Stevens. 1994. Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing. J. Infect. Dis. 170:173-179.
42. Buchanan, A. G., P. D. Riben, E. N. Rayner, S. E. Parker, A. R. Ronald, and T. J. Louie. 1985. Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: correlation of colonization and clinical outcome. Clin. Invest. Med. 8:139-147.
43. Burch, P. A., J. E. Karp, W. G. Merz, J. E. Kuhlman, and E. K. Fishman. 1987. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J. Clin. Oncol. 5:1985-1993.
44. Cafferkey, M. T. 1994. Chemoprophylaxis of invasive pulmonary aspergillosis. J. Antimicrob. Chemother. 33:917-924.
45. Caillot, D., O. Casasnovas, and E. Solary. 1993. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidemia in neutropenic patients. Antimicrob. Agents Chemother. 31:161-169.
46. Caillot, D., C. Durand, O. Casasnovas, J. F. Couaillier, A. Bernard, M. Buisson, E. Solary, A. Brachet, B. Cuisenier, A. Bonnin, V. Debuche, A. De Montaignac, G. Magnin, L. Arnould, T. Petrella, and H. Guy. 1995. Aspergillose pulmonaire invasive des patients neutropéniques. Ann. Med. Interne (Paris) 146:84-90.
47. Cameron, M. L., W. A. Schell, S. Bruch, J. A. Bartlett, H. A. Waskin, and J. R. Perfect. 1993. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 37:2449-2453.
48. Cap, J., A. Mojzesova, E. Kayserova, E. Bubanska, K. Hatiar, J. Trupl, and V. Krcmery, Jr. 1993. Fluconazole in children: first experience with prophylaxis in chemotherapy-induced neutropenia in pediatric patients with cancer. Chemother. 39:438-442.
49. Carpentieri, U., M. E. Haggard, L. H. Lockhart, L. P. Gustavson, Q. T. Box, and E. F. West. 1978. Clinical experience in prevention of candidiasis by nystatin in children with acute lymphocytic leukemia. J. Pediatr. 92:593-595.
50. Casasnovas, R. O., D. Caillot, E. Solary, B. Bonotte, P. Chavanet, A. Bonin, P. Camerlynck, and H. Guy. 1992. Prophylactic fluconazole and Candida krusei infections. N. Engl. J. Med. 326:891-892.
51. Castaldo, P., R. J. Stratta, R. P. Wood, R. S. Markin, K. D. Patil, M. S. Shaefer, A. N. Langnas, E. C. Reed, S. Li, T. J. Pillen, and B. W. Shaw, Jr. 1991. Fungal disease in liver transplant recipients: a multivariate analysis of risk factors. Transplant. Proc. 23:1517-1519.
52. Chandrasekar, P. H., and C. M. Gatny. 1994. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Chemotherapy 40:136-143.
53. Chandrasekar, P. H., C. M. Gatny, and the Bone Marrow Transplantation Team. 1994. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. J. Antimicrob. Chemother. 33:309-318.
54. Charak, B. S., P. M. Parikh, S. D. Banavali, A. Modi, T. K. Saikia, R. Gopal, and S. H. Advani. 1988. Comparison of clotrimazole with nystatin in preventing oral candidiasis in neutropaenic patients. Indian J. Med. Res. 88:416-420.
55. Chavanet, P., J. Lopez, M. Grappin, A. Bonnin, M. Duong, A. Waldner, M. Buisson, P. Camerlynck, and H. Portier. 1994. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. AIDS 8:945-950.
56. Cheson, B. D. 1995. Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol. 13:2431-2448.
57. Chow, K. Y., S. S. Lee, K. H. Wong, and T. M. Y. Choi. 1996. Major fungal infection among AIDS patients in Hong Kong, abstr. 102007. In Abstracts of the 7th International Congress for Infectious Diseases.
58. Chuck, S. L., and M. A. Sande. 1989. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N. Engl. J. Med. 321: 794-799.
59. Clemons, K. V., E. Brummer, and D. A. Stevens. 1994. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob. Agents Chemother. 38:460-464.
60. Cohen, M. S., R. E. Isturitz, and H. L. Malech. 1981. Fungal infection in chronic granulomatous disease. Am. J. Med. 71:59-66.
61. Cole, G. T., A. A. Halawa, and E. J. Anaissie. 1996. The role of the gastrointestinal tract in hematogeneous candidiasis: from the laboratory to the bedside. Clin. Infect. Dis. 22(Suppl. 2):S73-S88.
62. Collins, L. A., M. H. Samore, M. S. Roberts, R. Luzzati, R. L. Jenkins, W. D. Lewis, and A. W. Karchner. 1994. Risk factors for early invasive fungal infections complicating orthotopic liver transplantation. J. Infect. Dis. 170:644-652.
63. Conneally, E., M. T. Cafferkey, P. A. Daly, C. T. Keane, and S. R. McCann. 1990. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant. 5:403-406.
64. Cowie, F., S. T. Meller, P. Cushing, and R. Pinkerton. 1994. Chemoprophylaxis for pulmonary aspergillosis during intensive chemotherapy. Arch. Dis. Child. 70:136-138.
65. Cunliffe, N. A., and D. W. Denning. 1995. Uncommon invasive mycoses in AIDS. AIDS 9:411-420.
66. Cushing, D., C. Bustamante, A. Devlin, R. Finley, and J. Wade. 1991. Aspergillus infection prophylaxis: amphotericin-B nose spray, a double-blind trial, abstr. 737. In Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
67. Cuttner, J., K. M. Troy, L. Funaro, R. Brenden, and E. J. Bottone. 1986. Clotrimazole treatment for prevention of oral candidiasis in patients with acute leukemia undergoing chemotherapy. Am. J. Med. 81:771-774.
68. Dale, D. C., M. Davis, and M. E. Vincent 1994. Use of Filgrastim (r met HuG CSF) in severe chronic neutropenia, p. 83-101. In G. Morstyn and T. M. Dexter (ed.), Filgrastim (r metHuG CSF) in clinical practice. Marcel Dekker, Inc., New York, N.Y.
69. Dauber, J. H., I. L. Paradis, and J. S. Dummer. 1990. Infectious complications in pulmonary allograft recipients. Clin. Chest Med. 11:291-308.
70. De Bock, R., I. Gyssens, and M. Peetermans. 1989. Aspergillus in pepper. Lancet 8:331-332. (Letter.)
71. Decruyenaere, J., F. Colardyn, D. Vogelaers, G. Claeys, U. Hesse, C. De Deyne, E. Hoste, N. Lutz-Dettinger, K. Vandewoude, and B. de Hemptinne. 1995. Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Transplant. Proc. 27:515-516.
72. De Gregorio, M. W., W. M. F. Lee, and C. A. Ries. 1982. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 50: 2780-2784.
73. Dekker, A. W., M. Rozenberg-Arska, J. J. Sixma, and J. Verhoef. 1981. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia. Ann. Intern. Med. 95:555-599.
74. Dekker, A. W., L. F. Verdonck, and M. Rozenberg-Arska. 1994. Infection prevention in autologous bone marrow transplantation and the role of protective isolation. Bone Marrow Transplant. 14:89-93.
75. Dellion, S., L. Improvisi, B. Dupont, and F. Dromer. 1995. Diversity among yeasts isolated from patients with AIDS and oral candidosis, especially regarding fluconazole susceptibility. J. Mycol. Med. 5:98-101.
76. Deng, Z., J. L. Ribas, D. W. Gibson, and D. H. Connor. 1988. Infection caused by P. marneffei in China and southeast Asia: review of eighteen published cases and report of four more Chinese cases. Rev. Infect. Dis. 10:640-652.
77. Denning, D. W. 1994. Invasive aspergillosis in immunocompromized patients. Curr. Opin. Infect. Dis. 7:456-462.
78. Denning, D. W., J. P. Donnelly, K. P. Hellreigel, J. Ito, P. Martino, and J. W. van't Wout. 1992. Antifungal prophylaxis during neutropenia or allogeneic bone marrow transplantation: what is the state of the art? Chemotherapy 38(Suppl. 1):43-49.
79. Denning, D. W., and D. A. Stevens. 1990. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev. Infect. Dis. 12:1147-1201.
80. Devi, S. J. N., R. Schneerson, W. Egan, T. J. Ulrich, D. Bryla, J. B. Robbins, and J. E. Bennett. 1991. Cryptococcus neoformans serotype A glucuronoxylomannan-protecin conjugate vaccines: synthesis, characterization, and immunogenicity. Infect. Immun. 59:3700-3707.
81. De Vries-Hospers, H. G., N. H. Mulder, D. T. Sleijfer, and H. K. van Saene. 1982. The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients. Infection 10:71-75.
82. Dismukes, W. E. 1993. Management of cryptococcosis. Clin. Infect. Dis. 17(Suppl. 2):507-512.
83. Donnelly, J. P., I. D. Starke, D. A. Galton, D. Catovsky, J. M. Goldman, and J. H. Darrell. 1984. Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J. Hosp. Infect. 5:83-91.
84. Dowling, R. D., N. Baladi, M. Zenati, J. S. Dummer, R. L. Kormos, J. M. Armitage, S. A. Yousem, R. L. Hardesty, and P. B. Griffith. 1990. Disruption of the aortic anastomosis after heart-lung transplantation. Ann. Thorac. Surg. 49:118-122.
85. Dromer, F., L. Improvisi, B. Dupont, M. Eliaszewicz, G. Pialoux, S. Fournier, and V. Feuillie. Oral transmission of Candida albicans between partners in HIV-infected couples could contribute to dissemination of fluconazole-resistant isolates. AIDS, in press.
86. Dromer, F., S. Mathoulin, B. Dupont, A. Laporte, and the French Cryptococcosis Study Group. 1996. Epidemiology of cryptococcosis in France: 9-year survey (1985-1993). Clin. Infect. Dis. 23:82-90.
87. Dubois, J., T. Bartter, J. Gryn, and M. R. Pratter. 1995. The physiologic effects of inhaled amphotericin B. Chest 108:750-753.
88. Dummer, J. S., A. Hardy, A. Poorsattar, and M. Ho. 1983. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 36:259-267.
89. Dupont, B. 1997. Unpublished data.
90. Dupont, B., O. Lortholary, A. Datry, M. Gentilini, I. Vinchon, and L. Guillevin. 1996. Imported histoplasmosis due to H. duboisii in France (1968-1994), abstr. K58. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
91. Egger, T., A. Gratwohl, A. Tichelli, M. Uhr, C. Stebler Gysi, J. Passweg, M. Pless, M. Wernli, U. Buser, J. Wuhrmann, R. Frei, C. Nissen, and B. Speck. 1995. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study. Support Care Cancer 3:139-146.
92. Ellis, M. E., H. Clink, P. Ernst, M. A. Halim, A. Padmos, D. Spence, M. Kalin, S. M. Hussain Qadri, J. Burnie, and W. Greer. 1994. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 13:3-11.
93. Esposito, R., A. Castagna, and C. U. Foppa. 1990. Maintenance therapy of oropharyngeal candidiasis in HIV-infected patients with fluconazole. AIDS 4:1033-1034.
94. Estey, E., A. Maksymiuk, T. Smith, V. Fainstein, M. Keating, K. B. McCredie, E. J. Freireich, and G. P. Bodey. 1984. Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole and a combination of the two. Arch. Intern. Med. 144:1562-1568.
95. Ezdinli, E. Z., D. D. O'Sullivan, L. P. Wasser, U. Kim, and L. Stutzman. 1979. Oral amphotericin for candidiasis in patients with hematologic neoplasms: an autopsy study. JAMA 242:258-260.
96. Ferretti, G. A., R. C. Ash, A. T. Brown, M. D. Parr, E. H. Romond, and T. T. Lillich. 1988. Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant. 3:483-493.
97. Fish, D. G., N. M. Ampel, J. N. Galgiani, C. L. Dols, P. C. Kelly, C. H. Johnson, D. Pappagianis, J. E. Edwards, R. B. Wasserman, R. J. Clark, D. Antonikis, R. A. Larsen, S. J. Englender, and E. A. Petersen. 1990. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore) 69:384-391.
98. Flanner, M. T., D. B. Simmons, H. Saba, P. Altus, P. M. Wallach, and H. M. Adelman. 1992. Fluconazole in the treatment of hepatosplenic candidiasis. Arch. Intern. Med. 152:406-408.
99. Fox, R., K. R. Neal, C. L. S. Leen, M. E. Ellis, and B. K. Mandal. 1991. Fluconazole-resistant Candida in AIDS. J. Infect. Dis. 22:201-204.
100. Fridkin, S. K., and W. R. Jarvis. 1996. Epidemiology of nosocomial fungal infections. Clin. Microbiol. Rev. 9:499-511.
101. Gallant, J. E., R. D. Moore, and R. E. Chaisson. 1994. Prophylaxis for opportunistic infections in patients with HIV infection. Ann. Intern. Med. 120:932-944.
102. Gamis, A. S., T. Gudnason, and G. S. Giebink. 1991. Disseminated infection with Fusarium in recipients of hone marrow transplants. Rev. Infect. Dis. 13:1077-1088.
103. Geletko, S. M., M. Segarra, K. H. Mayer, T. C. Fiore, F. A. Bettencourt, T. P. Flanigan, and M. N. Dudley. 1996. Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Antimicrob. Agents Chemother. 40:1338-1341.
104. Gerson, S. L., G. H. Talbot, S. Hurwitz, B. L. Strom, E. J. Lusk, and P. Cassileth. 1984. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann. Intern. Med. 100:345-351.
105. Ghannoum, M. A. 1996. Is antifungal susceptibility testing useful in guiding fluconazole therapy. Clin. Infect. Dis. 22(Suppl. 2):S161-S165.
106. Girardin, H., J. Sarfati, F. Traore, J. Dupouy-Camet, F. Derouin, and J. P. Latge. 1994. Molecular epidemiology of nosocomial invasive aspergillosis. J. Clin. Microbiol. 32:684-690.
107. Girmenia, C., P. Martino, and A. Cassone. 1996. Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies. Blood 87:838-839.
108. Gluckman, E., H. Esperou-Bourdeau, P. Ribaud, A. Devergie, I. Hirsch, F. Traore, and F. Derouin. 1993. Comparaison entre le fluconazole et le kétoconazole pour la prophylaxie des infections fungiques chez les patients traités par greffe de moelle osseuse allogénique. Cah. Oncol. 2:167-169.
109. Goa, K. L., and L. B. Barradell. 1995. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 50:658-690.
110. Goldani, L. Z., D. E. Craven, and A. M. Sugar. 1995. Central venous catheter infection with Rhodotorula minuta in a patient with AIDS taking suppressive doses of fluconazole. J. Med. Vet. Mycol. 33:267-270.
111. Goldani, L. Z., and A. M. Sugar. 1995. Paracoccidioidomycosis and AIDS: an overview. Clin. Infect. Dis. 21:1275-1281.
112. Goldstein, D. J., N. G. El-Amir, R. C. Ashton, Jr., K. Catanese, E. A. Rose, H. R. Levin, and M. C. Oz. 1995. Fungal infections in left ventricular assist device recipients. Incidence, prophylaxis, and treatment. ASAIO J. 41:873-875.
113. Gombert, M. E., L. du Bouchet, T. M. Aulicino, and K. M. Butt. 1987. A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplants. Use in prophylaxis of oropharyngeal candidiasis. JAMA 258:2553-2555.
114. Gomez, F. J., A. M. Gomez, and G. S. Deepe, Jr. 1992. An 80-kilodalton antigen from Histoplasma capsulatum that has homology to heat shock protein 70 induces cell-mediated immune responses and protection in mice. Infect. Immun. 60:2565-2571.
115. Gonzalez, C. E., D. Venzon, S. Lee, B. U. Mueller, P. A. Pizzo, and T. J. Walsh. 1996. Risk factors for fungemia in children infected with human immunodeficiency virus: a case-control study. Clin. Infect. Dis. 23:515-521.
116. Goodley, J. M., Y. M. Clayton, and R. J. Hay. 1994. Environmental sampling for Aspergillus during building construction on a hospital site. J. Hosp. Infect. 26:27-35.
117. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stif, D. J. Friedman, W. G. Powderly, J. L. Silber, H. Horowitz, A. Lichtin, S. N. Wolff, K. F. Mangan, S. M. Silver, D. Weisdorf, W. G. Ho, G. Gilbert, and D. Buell. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
118. Goodrich, J. M., E. C. Reed, M. Mon, L. D. Fisher, S. Skerett, P. S. Dandliker, B. Klis, G. W. Counts, and J. D. Meyers. 1991. Clinical features and analysis of risk factors for invasive candidat infection after marrow transplantation. J. Infect. Dis. 164:731-740.
119. Gorensek, M. J., W. D. Carey, J. A. Washington II, D. P. Vogt, T. A. Broughan, and M. W. Westveer. 1993. Selective bowel decontamination with quinolones and nystatin reduces gram-negative and fungal infections in orthotopic liver transplant recipients. Cleveland Clin. J. Med. 60:139-144.
120. Graybill, J. R. 1995. Systemic mycoses in the 21st century. Infect. Dis. Clin. North Am. 9:297-311.
121. Graybill, J. R. 1996. The future of antifungal therapy. Clin. Infect. Dis. 22(Suppl. 2):S166-S178.
122. Gryn, J., J. Goldberg, E. Johnson, J. Siegel, and J. Inzerillo. 1993. The toxicity of daily inhaled amphotericin B. Am. J. Clin. Oncol. 16:43-46.
123. Guiot, H. F. L., and W. E. Fibbe. 1996. Prevention of oral candidiasis and systemic fungal infection in patients with hematologic malignancies. J. Mycol. Méd. 6(Suppl. II):26-30.
124. Guiot, H. F. L., W. E. Fibbe, and J. K. van't Wout. 1994. Risk factors for fungal infections in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin. Infect. Dis. 18:525-532.
125. Gustafson, T. L., W. Schaffner, G. B. Lavely, C. W. Stratton, H. K. Johnson, and R. H. Hutcheson. 1983. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J. Infect. Dis. 148:230-238.
126. Hadley, S., and A. W. Karchmer. 1995. Fungal infections in solid organ transplant recipients. Infect. Dis. Clin. North Am. 9:1045-1074.
127. Hadley, S., M. H. Samore, D. W. Lewis, R. L. Jenkins, A. W. Karchmer, and S. M. Hammer. 1995. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 59:851-859.
128. Hagensee, M. E., J. E. Bauwens, B. Kjos, and R. A. Bowden. 1994. Brain abscess following marrow transplantation: experience at the Fred Hutchinson cancer research center, 1984-1992. Clin. Infect. Dis. 19:402-408.
129. Hajjeh, R., M. Farley, W. Baughman, A. Reingold, G. Rothrock, R. Hamill, E. Graviss, P. Pappas, C. Thomas, L. Klug, L. Hutwagner, and R. Pinner. 1996. Multistate population-based surveillance for cryptococcal disease: 1992-94, abstr. 153. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
130. Hajjeh, R. A. 1995. Disseminated histoplasmosis in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 21(Suppl. 1):S108-S110.
131. Hann, I. M., H. G. Prentice, R. Corringham, H. A. Blacklock, M. Keaney, M. Shannon, P. Noone, E. Gascoigne, J. Fox, E. Boesen, M. Szawatkowski, and A. V. Hoffbrand. 1982. Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet i:826-829.
132. Hansen, R. M., N. Reinerio, P. G. Sohnle, R. A. Abrams, P. S. Ritch, J. A. Libnoch, and T. Anderson. 1987. Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study. Arch. Intern. Med. 147:710-712.
133. Havlir, D. V., S. A. Bozzette, J. A. McCutchan, M. Dunne, and CCTG-MOPPS-Study-Investigators. 1996. A double-blind, randomized study of weekly versus daily fluconazole for the prevention of fungal infections in AIDS patients, abstr. 568. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections 1996.
134. Heald, A. E., G. M. Cox, W. A. Schell, J. A. Bartlett, and J. R. Perfect. 1996. Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. AIDS 10:263-268.
135. Herbrecht, R., and C. Cordonnier. 1995. Impact of cytokines and growth factors in the antifungal armamentarium, p. 141-155. In F. Meunier (ed.), Baillière's clinical infectious diseases. Baillière Tindall, London, U.K.
136. Hertenstein, B., W. V. Kern, T. Schmeiser, M. Stefanic, D. Bunjes, M. Wiesneth, J. Novotny, H. Heimpel, and R. Arnold. 1994. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann. Hematol. 68:21-26.
137. Hesse, U. J., D. E. R. Sutherland, J. S. Najarian, and R. L. Simmons. 1986. Intraabdominal infections in pancreas transplant recipients. Ann. Surg. 203:153-162.
138. Hibberd, P. L., and R. H. Rubin. 1994. Clinical aspects of fungal infection in organ transplant recipients. Clin. Infect. Dis. 19(Suppl. 1):S33-S40.
139. Hiemenz, J. W., and J. N. Greene. 1993. Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation. Hematol. Oncol. Clin. North Am. 7:961-1002.
140. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2): S133-S144.
141. Hofstra, W., H. G. de Vries-Hospers, and D. van der Waajj. 1979. Concentrations of nystatin in faeces after oral administration of various doses of nystatin. Infection 7:166-170.
142. Hofstra, W., H. G. de Vries-Hospers, and D. van der Waaij. 1982. Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses. Infection 10:223-227.
143. Hoppe, J. E., T. Klingebiel, and D. Niethammer. 1994. Selection of Candida glabrata in pediatric bone marrow transplant recipients receiving fluconazole. Pediatr. Hematol. Oncol. 11:207-210.
144. Hummel, M., U. Thalmann, G. Jautzke, F. Staib, M. Seibold, and R. Hetzer. 1992. Fungal infections following heart transplantation. Mycoses 35:23-34.
145. Hunt, K. E., and B. J. Glasgow. 1996. Aspergillus endophtalmitis. An unrecognized endemic disease in orthotopic liver transplantation. Ophthalmology 103:757-767.
146. Hunter, A. E., A. P. Haynes, and N. H. Russell. 1995. Bone marrow transplantation: current situation, complications and prevention. J. Antimicrob. Chemother. 36(Suppl. B):119-133.
147. Imwidthaya, P. 1994. One year's experience with Cryptococcus neoformans in Thailand. Trans. R. Soc. Trop. Med. Hyg. 88:208.
148. Jabbour, N., J. Reyes, S. Kusne, M. Martin, and J. Fung. 1996. Cryptococcal meningitis after liver transplantation. Transplantation 61:146-149.
149. Jaffe, H. S. 1992. The interferons: a clinical overview, p. 1-7. In H. S. Jaffe, L. R. Bucalo and S. A. Sherwin (ed.), Anti-infective applications of interferon gamma. Marcel Dekker, Inc., New York.
150. Jeffery, G. M., M. E. Beard, R. B. Ikram, J. Chua, J. R. Allen, D. C. Heaton, D. N. Hart, and M. I. Schousboe. 1991. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am. J. Med. 90:685-692.
151. Jones, J. L., P. L. Fleming, C. A. Ciesielski, D. J. Hu, J. E. Kaplan, and J. W. Ward. 1995. Coccidioidomycosis among persons with AIDS in the United States. J. Infect. Dis. 171:961-966.
152. Jones, P. G., C. A. Kauffman, L. S. McAuliffe, M. K. Liepman, and A. G. Bergman. 1984. Efficacy of ketoconazole vs nystatin in prevention of fungal infections in neutropenic patients. Arch. Intern. Med. 144:549-551.
153. Jorgensen, C., F. Dreyfus, J. Vaixeler, S. Guyomard, C. Massiot, C. Belanger, F. Brunet, T. Giraud, and P. Dupuis-Camay. 1989. Failure of amphotericin B spray to prevent aspergillosis in granulocytopenic patients. Nouv. Rev. Fr. Hematol. 31:327-328.
154. Just-Nubling, G., G. Gentschew, K. Meibner, J. Odewald, S. Staszewski, E. B. Helm, and W. Stille. 1991. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur. J. Clin. Microbiol. Infect. Dis. 10:917-921.
155. Kanj, S. S., K. Welty-Wolf, J. Madden, V. Tapson, M. A. Baz, R. Duane Davis, and J. R. Perfect. 1996. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine (Baltimore) 75:142-156.
156. Karabinis, A., C. Hill, B. Leclercq, C. Tancrede, D. Baume, and A. Andremont. 1988. Risk factors for candidemia in cancer patients: a case-control study. J. Clin. Microbiol. 26:429-432.
157. Karp, J. E., P. Burch, and W. G. Merz. 1988. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am. J. Med. 85:203-206.
158. Kauffman, C. A., S. F. Bradley, S. C. Ross, and D. R. Weber. 1991. Hepatosplenic candidiasis successful treatment with fluconazole. Am. J. Med. 91:137-141.
159. Kelly, S. L., D. C. Lamb, D. E. Kelly, J. Loeffier, and H. Einsele. 1996. Resistance to fluconazole and amphotericin B in Candida albicans from AIDS patients. Lancet 348:1523-1524.
160. Khoo, S., and D. W. Denning. 1994. Aspergillus infection in the acquired immunodeficiency syndrome. Clin. Infect. Dis. 19(Suppl. 1):541-548.
161. Kirkland, T. N., and J. Fierer. 1996. Coccidioidomycosis: a reemerging infectious disease. Emerg. Infect. Dis. 2:192-199.
162. Kramer, M. R., S. E. Marshall, V. A. Starnes, P. Gamberg, Z. Amitai, and J. Theodore. 1993. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch. Intern. Med. 153:2010-2016.
163. Kullberg, B. J., J. W. van't Wout, C. Hoogstraten, and R. van Furth. 1993. Recombinant Interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice. J. Infect. Dis. 168:436-443.
164. Kung, N., N. Fisher, B. Gunson, M. Hastings, and D. Mutimer. 1995. Fluconazole prophylaxis for high-risk liver transplant recipients. Lancet 345:1234-1235.
165. Kunova, A., J. Trupl, S. Spanik, L. Drgona, J. Sufliarsky, J. Lacka, V. Studena, E. Hlavacova, M. Studena, E. Kukuckova, T. Kollar, P. Pichna, E. Oravcova, and V. Krcmery Jr. 1995. Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole. Chemotherapy 41:39-44.
166. Kusne, S., J. S. Dummer, N. Singh, S. Iwatsuki, L. Makowka, C. Esquivel, A. G. Tzakis, T. E. Starzl, and M. Ho. 1988. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 67:132-143.
167. Kusne, S., J. Torres-Cisneros, R. Manez, W. Irish, M. Martin, J. Fung, R. L. Simmons, and T. E. Starzl. 1992. Factors associated with invasive lung aspergillosis and the significance of positive culture after liver transplantation. J. Infect. Dis. 166:1379-1383.
168. Laguna, F., J. L. Rodriguez-Tudela, and A. Enriquez. 1994. Fungemia due to fluconazole-resistant Candida albicans in a patient with AIDS. Clin. Infect. Dis. 19:542-543.
169. Laine, L., R. H. Dretler, C. N. Conteas, C. Tuazon, F. M. Koster, F. Sattler, K. Squires, and M. Z. Islam. 1992. Fluconazole compared with ketoconazole for the treatment of Candida esophagitis in AIDS. A randomized trial. Ann. Intern. Med. 117:655-660.
170. Lake-Bakaar, G., W. Tom, D. Lake-Bakaar, N. Gupta, S. Beidas, M. Elsakr, and E. Straus. 1988. Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 109:471-473.
171. Lam, H. H., and B. L. Althaus. 1995. Antifungal prophylaxis in bone marrow transplant. Ann. Pharmacother. 29:921-924.
172. Lange, B., S. Halpern, G. Gale, and S. Kramer. 1984. Trimethoprimsulfamethoxazole and nystatin prophylaxis in children with acute lymphoblastic leukemia. Eur. Pediatr. Haematol. Oncol. 1:231-238.
173. Launay, O., O. Lortholary, B. Jarrousse, M. Bentata, C. Bouges-Michel, A. Groc, P. Casassus, and L. Guillevin. 1996. Candidemia in 13 HIV-infected adults, abstr. 1136. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
174. Le, T. P., C. U. Tuazon, M. Levine, M. Borum, and C. Rollhauser. 1996. Resistance to fluconazole and amphotericin B in a patient with AIDS who was being treated for candidal esophagitis. Clin. Infect. Dis. 23:649-650.
175. Lee, J. W., N. L. Seibel, M. Amantea, P. Witcomb, P. A. Pizzo, and T. J. Walsh. 1993. Safety, tolerance, and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr. 120:987-993.
176. Leen, C. L. S., E. M. Dunbar, M. E. Ellis, and B. K. Mandal. 1990. Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J. Infect. 21:55-60.
177. Le Moing, V., O. Lortholary, P. Casassus, L. Guillevin, and B. Dupont. 1995. Traitement des aspergilloses par l'itraconazole. Med. Mal. Infect. 25:50-57.
178. Lieschke, C. J., and A. W. Burgess. 1992. Granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor. II. N. Engl. J. Med. 327:99-106.
179. Lopez-Berestein, G., R. L. Hopfer, R. Mehta, K. Mehta, E. M. Hersh, and R. L. Juliano. 1984. Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25:366-367.
180. Lortholary, O. Unpublished data.
181. Lortholary, O. Unpublished data.
182. Lortholary, O., B. Dupont, M. C. Meyohas, W. Rozenbaum, A. Datry, I. L. Vinchon, and L. Guillevin. 1996. Imported histoplasmosis due to H. capsulatum in HIV-infected patients in France, abstr. I174. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
183. Lortholary, O., T. Généreau, B. Jarrousse, and L. Guillevin. 1996. Maladies systémiques et infections: questions actuelles. Presse Med. 25:370-378.
184. Lortholary, O., L. Guillevin, and B. Dupont. 1995. Les manifestations extra-respiratoires de l'aspergillose invasive humaine. Ann. Med. Interne (Paris) 146:96-101.
185. Lortholary, O., L. Guillevin, and B. Dupont. 1995. Les mycoses invasives rares au cours du SIDA, p. 75-86. In F. Vachon, P. Yeni, J. P. Coulaud, J. L. Vildé, and J. P. Pocidalo (ed.), Le traitement des mycoses systémiques. Journées de l'Hôpital Claude-Bernard, Librairie Arnette, Paris, France.
186. Lortholary, O., L. Guillevin, B. Dupont, and E. Drouhet. 1995. Traitement des histoplasmoses et de la coccidioidomycose. Med. Mal. Infect. 25:63-73.
187. Lortholary, O., O. Launay, B. Jarrousse, C. Bouges-Michel, Y. Cohen, L. Guillevin, and P. Casassus. 1996. Candidemia in a French university hospital: analysis of 58 cases (1989-1995), abstr. 29019. In Abstracts of the 7th International Congress for Infectious Diseases 1996.
188. Lortholary, O., M. C. Meyohas, B. Dupont, J. Cadranel, D. Salmon-Ceron, D. Peyramond, and D. Simonin. 1993. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. Am. J. Med. 95:177-187.
189. Loudon, K. W., A. P. Coke, J. P. Burnie, G. S. Lucas, and J. A. Liu Yin. 1994. Invasive aspergillosis: clusters and sources? J. Med. Vet. Mycol. 32:217-224.
190. Louie, A., A. L. Baltch, R. P. Smith, M. A. Franke, W. J. Ritz, J. K. Singh, and M. A. Gordon. 1994. Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect. Immun. 62:2761-2772.
191. Lumbreras, C., V. Cuervas-Mons, P. Jara, A. del Palacio, V. S. Turrion, C. Barrios, E. Moreno, A. R. Noriega, and C. V. Paya. 1996. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J. Infect. Dis. 174:583-588.
192. Lumbreras, C., I. Fernandez, J. Velosa, S. Munn, S. Sterioff, and C. V. Paya. 1996. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin. Infect. Dis. 20:514-520.
193. Lupinetti, F. M., D. M. Benrendt, R. H. Giller, M. E. Trigg, and P. De Alarcon. 1992. Pulmonary resection for fungal infection in children undergoing bone marrow transplantation. J. Thorac. Cardiovasc. Surg. 104:684-687.
194. Maenza, J. R., J. C. Keruly, R. D. Moore, R. E. Chaisson, W. G. Merz, and J. E. Gallant. 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 173:219-225.
195. Maenza, J. R., W. G. Merz, M. J. Romagnoli, J. C. Keruly, R. D. Moore, and J. E. Gallant. 1997. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin. Infect. Dis. 24:28-34.
196. Manfredi, R., A. Mastroianni, O. Coronado, and F. Chiodo. 1996. Evaluation of fluconazole as primary antifungal prophylaxis in HIV-infected patients with advanced immune deficiency, abstr. 1175. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
197. Martinez-Marcos, F., J. Cisneros, M. Gentil, G. Algarra, P. Pereira, J. Aznar, and J. Pachon. 1994. Prospective study of renal transplant infections in 50 consecutive patients. Eur. J. Clin. Microbiol. Infect. Dis. 13:1023-1028.
198. Martino, P., C. Girmenia, M. Venditti, A. Micozzi, S. Santilli, V. L. Burgio, and F. Mandelli. 1989. Candida colonization and systemic infection in neutropenic patients. A retrospective study. Cancer 64:2030-2034.
199. Martino, R., J. Nomdedeu, A. Altes, A. Sureda, S. Brunet, C. Martinez, and A. Domingo-Albois. 1994. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases. Bone Marrow Transplant. 13:265-269.
200. McKinsey, D., J. Wheat, G. Cloud, H. Gutsch, C. Thomas, B. Wiesinger, B. Moscovitz, D. Bamberger, T. Slama, M. Pierce, L. Lancaster, D. Lancaster, M. Threlkeld, W. Dismukes, and C. Kauffman. 1996. Itraconazole is effective primary prophylaxis against systemic fungal infections in patients with advanced HIV infection, abstr. LB9. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
201. McKinsey, D. S., M. R. Gupta, M. R. Driks, D. L. Smith, and M. O'Connor. 1992. Histoplasmosis in patients with AIDS: efficacy of maintenance amphotericin B therapy. Am. J. Med. 92:225-227.
202. McKinsey, D. S., M. R. Gupta, S. A. Riddler, M. R. Driks, D. L. Smith, and P. J. Kurtin. 1989. Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 111:655-659.
203. McNeil, M. M., and N. M. Ampel. 1995. Opportunistic coccidioidomycosis in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin. Infect. Dis. 21(Suppl. 1):S111-S113.
204. McQuillen, D. P., B. S. Zingman, F. Meunier, and S. M. Levitz. 1992. Invasive infections due to Candida krusei: report of ten cases of fungemia that include three cases of endophthalmitis. Clin. Infect. Dis. 14:472-178.
205. McWhinney, P. H. M., C. C. Kibbler, M. D. Hamon, O. P. Smith, L. Gandhi, L. A. Berger, R. K. Walesby, A. V. Hoffbrand, and H. G. Prentice. 1993. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin. Infect. Dis. 17:397-404.
206. Menichetti, F., A. Del Favero, P. Martino, G. Bucaneve, A. Micozzi, D. D'Antonio, P. Ricci, M. Carotenuto, V. Liso, A. M. Nosari, T. Barbui, G. Fasola, and F. Mandelli. 1994. The GIMEMA Infection Program. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann. Intern. Med. 120:913-918.
207. Merz, W. G., J. E. Karp, M. Hoagland, M. Jett-Goheen, J. M. Junkins, and F. Hood. 1988. Diagnosis and successful treatment of fusariosis in the compromised host. J. Infect. Dis. 158:1046-1055.
208. Merz, W. G., J. E. Karp, D. Schron, and R. Saral. 1986. Increased incidence of fungemia caused by Candida krusei. J. Clin. Microbiol. 24:581-584.
209. Meunier, F. 1987. Prevention of mycoses in immunocompromised patients. Rev. Infect. Dis. 9:408-416.
210. Meunier, F., M. Aoun, M. Janssens, C. Dekoster, and M. Paesmans. 1991. Chemoprophylaxis of fungal infections in granulocytopenic patients using fluconazole vs oral amphotericin B. Drug Invest. 3:258-265.
211. Meunier, F., M. Paesmans, and P. Autier. 1994. Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients. Eur. J. Cancer 308:196-199.
212. Meunier-Carpentier, F. 1984. Chemoprophylaxis of fungal infections. Am. J. Med. 76:652-656.
213. Meunier-Carpentier, F., M. Cruciani, and J. Klastersky. 1983. Oral prophylaxis with miconazole or ketoconazole of invasive fungal disease in neutropenic cancer patients. Eur. J. Cancer Clin. Oncol. 19:43-48.
214. Meunier-Carpentier, F., R. Snoeck, J. Gerain, C. Muller, and J. Klastersky. 1984. Amphotericin B nasal spray as prophylaxis against aspergillosis in patients with neutropenia. N. Engl. J. Med. 311:1056.
215. Meyers, J. D., and K. Atkinson. 1983. Infection in bone marrow transplantation. Clin. Haematol. 12:791-811.
216. Milliken, S. T., and R. L. Powles. 1990. Antifungal prophylaxis in bone marrow transplantation. Rev. Infect. Dis. 12(Suppl. 3):S374-S379.
217. Mitchell, T. G., and J. R. Perfect. 1995. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin. Microbiol. Rev. 8:515-548.
218. Momin, F., and P. H. Chandrasekar. 1995. Antimicrobial prophylaxis in bone marrow transplantation. Ann. Intern. Med. 123:205-215.
219. Mora, N. P., G. Klintmalm, H. Solomon, R. M. Goldstein, T. A. Gonwa, and B. S. Husberg. 1992. Selective amphotericin B prophylaxis in the reduction of fungal infections after liver transplant. Transplant. Proc. 24:154-155.
220. Moreau, P., N. Milpied, N. Fayette, J. F. Ramée, and J. L. Harousseau. 1992. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J. Antimicrob. Chemother. 30:535-541.
221. Moreau, P., J. R. Zahar, N. Milpied, O. Baron, B. Mahé, D. Wu, P. Germaud, P. Despins, A. Y. Delajartre, and J. L. Harousseau. 1993. Localized invasive pulmonary aspergillosis in patients with neutropenia. Effectiveness of surgical resection. Cancer 72:3223-3226.
222. Morganstern, G. R., R. Powles, B. Robinson, and T. J. McElwain. 1982. Cyclosporine interaction with ketoconazole and melphalan. Lancet ii:1342.
223. Morrison, V. A., R. J. Haake, and D. J. Weisdorf. 1994. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am. J. Med. 96:497-503.
224. Mossad, S. B., D. L. Longworth, M. Goormastic, J. M. Serkey, T. F. Keys, and B. J. Bolwell. 1996. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant. 18:265-271.
225. Mouy, R., C. Bremard, A. Fischer, P. Huu Trong, E. Vilmer, and C. Griscelli. 1985. Aspergillus infection and chronic septic granulomatosis. Arch. Fr. Pediatr. 42(Suppl. 2):953-957.
226. Mouy, R., F. Veber, S. Blanche, J. Donadieu, R. Brauner, J. C. Levron, C. Griscelli, and A. Fischer. 1994. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J. Pediatr. 125:998-1003.
227. Muhm, M., A. Zuckermann, R. Prokesch, J. Pammer, M. Hiesmayr, and W. Haider. 1996. Early onset of pulmonary mucormycosis with pulmonary vein thrombosis in a heart transplant recipient. Transplantation 62:1185-1187.
228. Myers, S. E., S. M. Devine, R. L. Topper, M. Ondrey, C. Chandler, K. O'Toole, S. F. Williams, R. A. Larson, and R. B. Geller. 1992. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leukemia Lymphoma 8:229-233.
229. Nadeem, I., V. Yeldandi, P. Sheridan, M. A. McCabe, A. Husain, A. Montoya, and E. R. Garrity. 1994. Efficacy of itraconazole prophylaxis for aspergillosis in lung transplant recipients. Clin. Infect. Dis. 19:620. (Abstract.)
230. Nelson, M. R., M. Fisher, J. Cartledge, T. Rogers, and B. G. Gazzard. 1994. The role of azoles in the treatment and prophylaxis of cryptococcal disease in HIV infection. AIDS 8:651-654.
231. Nelson, S., R. Daifuku, and J. Andersen. 1994. Use of Filgrastim (r metHuG CSF) in infectious diseases, p. 253-266. In G. Morstyn and T. M. Dexter (ed.), Filgrastim (rmetHuG CSF) in clinical practice. Marcel Dekker. Inc., New York, N.Y.
232. Nemunaitis, J., C. Anasetti, R. Storb, J. A. Bianco, C. D. Buckner, N. Onetto, P. Martin, J. Sanders, K. Sullivan, M. Mori, K. Shannon-Dorcy, R. Bowden, F. R. Appelbaum, J. Hansen, and J. W. Singer. 1992. Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 79:2572-2577.
233. Nemunaitis, J., J. D. Meyers, C. D. Buckner, K. Shannon-Dorcy, M. Mori, H. Shulman, J. A. Bianco, C. S. Higano, E. Groves, R. Storb, J. Hansen, F. R. Appelbaum, and J. W. Singer. 1991. Phase I trial of recombinant human macrophage colony stimulating-factor in patients with invasive fungal infections. Blood 78:907-913.
234. Newman, S. L., T. P. Flanigan, A. Fisher, M. G. Rinaldi, M. Stein, and K. Vigilante. 1994. Clinically significant mucosal candidiasis resistant to fluconazole in patients with AIDS. Clin. Infect. Dis. 19:684-686.
235. Newton, J. A., Jr., S. A. Tasker, W. D. Bone, E. C. Olfield III, P. E. Olson, M.-T. Nguyen, and M. R. Wallace. 1995. Weekly fluconazole for the suppression of recurrent thrush in HIV-seropositive patients: impact on the incidence of disseminated cryptococcal infection. AIDS 9:1286-1287. (Letter.)
236. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
237. Nicholl, T. A., C. R. Nimmo, J. D. Shepherd, P. Phillips, and P. J. Jewesson. 1995. Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions. Ann. Pharmacother. 29:1081-1087.
238. Nightingale, S. D., S. X. Cal, D. M. Peterson, S. D. Loss, B. A. Gamble, D. A. Watson, C. P. Manzone, J. E. Baker, and J. D. Jockusch. 1992. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 6:191-204.
239. Niki, Y., E. M. Bernard, F. F. Edwards, H. J. Schmitt, B. Yu, and D. Armstrong. 1991. Model of recurrent pulmonary aspergillosis in rats. J. Clin. Microbiol. 29:1317-1322.
240. Ninane, J., and a Multicentre Study Group. 1994. A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 13:330-337.
241. Ninane, J., T. Sluysmans, C. Vermylen, K. De Beule, R. Woestenborghs, G. Cauwenbergh, and G. Cornu. 1989. Itraconazole versus ketoconazole for the prophylaxis of fungal infection in neutropenic children: results of two consecutive nonrandomized studies. Pediatr. Hematol. Oncol. 6:349-353.
242. Norris, S., J. Wheat, D. McKinsey, D. Lancaster, B. Katz, J. Black, M. Driks, R. Baker, K. Israel, D. Traeger, S. Moriarity, J. Fraiz, D. Webb, and T. Slama. 1994. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am. J. Med. 96: 504-508.
243. Nosanchuk, J. D., K. A. Sepkowitz, R. N. Pearse, M. H. White, S. D. Nimer, and D. Armstrong. 1996. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant. 18:355-359.
244. O'Donnell, M., G. M. Schmidt, B. R. Tegtmeier, C. Faucett, J. L. Fahey, J. Ito, A. Nademanee, J. Niland, P. Parker, E. P. Smith, et al. 1994. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J. Clin. Oncol. 12:827-834.
245. Ostroff, S. M., R. A. Spiegel, J. Feinberg, C. A. Benson, and C. R. Horsburgh, Jr. 1995. Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 21(Suppl. 1):S72-S76.
246. Owens, N. J., C. H. Nightingale, R. T. Schweizer, P. K. Schauer, P. T. Dekker, and R. Quintiliani. 1984. Prophylaxis of oral candidiasis with clotrimazole troches. Arch. Intern. Med. 144:290-293.
247. Palmblad, J., B. Lonnqvist, B. Carlsson, G. Grimfors, M. Jarnmark, R. Lerner, P. Ljungman, C. Nystrom-Rosander, B. Petrini, and G. Oberg. 1992. Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukemia in adults: more bacteraemias. J. Intern. Med. 231:363-370.
248. Pappagianis, D., and the Valley Fever Vaccine Study Group. 1993. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in man. Am. Rev. Respir. Dis. 148:656-660.
249. Pappas, P. G., J. C. Pottage, W. G. Powderly, V. J. Fraser, C. W. Stratton, S. McKenzie, M. L. Tapper, H. Chmel, and F. C. Bonebrake. 1992. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 116:847-853.
250. Patel, R., and C. V. Paya. 1997. Infections in solid-organ transplant recipients. Clin. Microbiol. Rev. 10:86-124.
251. Patel, R., D. Portela, A. D. Badley, W. S. Harmsen, J. J. Larsonkeller, D. M. Ilstrup, M. R. Keating, R. H. Wiesner, R. A. F. Krom, and C. V. Paya. 1996. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 62:926-934.
252. Patterson, T. F., J. Peters, S. M. Levine, A. Anzueto, C. L. Bryan, E. Y. Sako, O. L. Miller, J. H. Calhoon, and M. G. Rinaldi. 1996. Systemic availability of itraconazole in lung transplantation. Antimicrob. Agents Chemother. 40:2217-2220.
253. Paya, C. V. 1993. Fungal infections in solid-organ transplantation. Clin. Infect. Dis. 16:677-688.
254. Perfect, J. R., and W. A. Schell. 1996. The new fungal opportunists are coming. Clin. Infect. Dis. 22(Suppl. 2):S112-S118.
255. Perfect, J. R., M. E. Klotman, C. C. Gilbert, D. D. Crawford, G. L. Rosner, K. A. Wright, and W. P. Peters. 1992. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J. Infect. Dis. 165:891-897.
256. Persons, D. A., M. Laughlin, D. Tanner, J. Perfect, J. P. Gockerman, and J. W. Hathorn. 1991. Fluconazole and Candida krusei fungemia. N. Engl. J. Med. 325:1315.
257. Peters, B. G., D. R. Adkins, B. R. Harrison, W. S. Velasquez, F. R. Dunphy, P. J. Petruska, C. E. Bowers, R. Niemeyer, W. McIntyre, D. Vrahnos, S. E. Auberry, and G. Spitzer. 1996. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Bone Marrow Transplant. 18:93-102.
258. Pfaller, M. 1994. Epidemiology and control of fungal infections. Clin. Infect. Dis. 19(Suppl. 1):S8-S13.
259. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22(Suppl. 2):S89-S94.
260. Pfaller, M. A., J. Rhine-Chalberg, S. W. Redding, J. Smith, G. Farinacci, A. W. Folhergill, and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32:59-64.
261. Philpott-Howard, J. N., J. J. Wade, G. J. Mufti, K. W. Brammer, G. Ehninger, and the Multicentre Study Group. 1993. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J. Antimicrob Chemother 31:973-984.
262. Pinner, R. W., R. A. Hajjeh, and W. G. Powderly. 1995. Prospects for preventing cryptococcosis in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 21(Suppl. 1):S103-S107.
263. Pittet, D., M. Monod, P. M. Suter, E. Frenk, and R. Auckenthaler. 1994. Candida colonization and subsequent infections in critically ill surgical patients. Ann. Surg. 220:751-758.
264. Pottage, J. C., Jr., and B. E. Sha. 1991. Development of histoplasmosis in a human immunodeficiency virus-infected patient receiving fluconazole. J. Infect. Dis. 164:622-623.
265. Powderly, W. G. 1996. Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22(Suppl. 2):S119-S123.
266. Powderly, W. G., D. M. Kinkelstein, J. Feinberg, P. Frame, W. He, C. Van der Horst, S. L. Koletar, M. E. Eyster, J. Carey, H. Waskin, T. M. Hooton, N. Hyslop, S. A. Spector, S. A. Bozzette, and the NIAID AIDS Clinical Trials Group. 1995. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 332: 700-705.
267. Powderly, W. G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84:826-832.
268. Powderly, W. G., M. S. Saag, G. A. Clood, P. Robinson, R. D. Meyer, J. M. Jacobson, J. R. Graybill, A. M. Sugar, V. J. McAuliffe, S. E. Follansbee, C. U. Tuazon, J. J. Stern, J. Feinberg, R. Hafner, and W. E. Dismukes. 1992. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 326:793-798.
269. Powles, L., and S. Milliken. 1991. The prophylaxis of fungal infections. J. Antimicrob. Chemother. 28(Suppl. A):97-103.
270. Prentice, A. G., and G. R. Bradford. 1989. Prophylaxis of fungal infections with itraconazole during remission induction therapy. Mycoses 32(Suppl. 1):96-102.
271. Prentice, A. G., D. W. Warnock, S. A. N. Johnson, M. J. Phillips, and D. A. Oliver. 1994. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J. Antimicrob. Chemother. 34:247-252.
272. Preston, S. L., and L. L. Briceland. 1995. Fluconazole for antifungal prophylaxis in chemotherapy-induced neutropenia. Am. J. Health Syst. Pharm. 52:164-173.
273. Quagliarello, V. J., C. Viscoli, and R. I. Horwitz. 1995. Primary prevention of cryptococcal meningitis by fluconazole in HIV-infected patients. Lancet 345:548-552.
274. Quirk, P. C., P. J. Osborne, and L. J. Walsh. 1995. Australian Dental Research Fund Trebitsch Scholarship. Efficacy of antifungal prophylaxis in bone marrow transplantation. Aust. Dent. J. 40:267-270.
275. Raakow, R., R. Steffen, B. Lefebre, W. O. Bechstein, G. Blumhardt, and P. Neuhaus. 1990. Selective bowel decontamination effectively prevents gram-negative bacterial infections after liver transplantation. Transplant. Proc. 22:1556-1557.
276. Reef, S. E., and K. H. Mayer. 1995. Opportunistic candidal infections in patients infected with human immunodeficiency virus: prevention issues and priorities. Clin. Infect. Dis. 21(Suppl. 1):S99-S102.
277. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. Van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, C. D. Webb, and the Candidemia Study Group and the NIAID Mycoses Study Group. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
278. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
279. Rhame, F. S. 1991. Prevention of nosocomial aspergillosis. J. Hosp. Infect. 18(Suppl. A):466-472.
280. Richet, H. M., A. Andremont, C. Tancrede, J. L. Pico, and W. R. Jarvis. 1991. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev. Infect. Dis. 13:211-215.
281. Riley, D. K., A. Pavia, P. G. Beatty, F. B. Petersen, J. L. Spruance, R. Stokes, and T. G. Evans. 1994. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am. J. Med. 97:509-514.
282. Robertson, M. J., and R. A. Larson. 1988. Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am. J. Med. 84:233-239.
283. Rogers, T. R. 1995. Epidemiology and control of nosocomial fungal infections. Curr. Opin. Infect. Dis. 8:287-290.
284. Roilides, E., and P. A. Pizzo. 1993. Perspectives on the use of cytokines in the management of infectious complications of cancer. Clin. Infect. Dis. 17(Suppl. 2):S385-S389.
285. Rossetti, F., D. L. Brawner, R. Bowden, W. G. Meyer, H. G. Scnoch, L. Fisher, D. Myerson, R. C. Hackman, H. M. Shulman, G. E. Sale, J. D. Meyers, and G. B. McDonald. 1995. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin. Infect. Dis. 20:801-811.
286. Rotstein, C., M. Cummings, J. Tidings, K. Killion, E. Powell, T. L. Gustafson, and D. Higby. 1985. An outbreak of invasive aspergillosis among allogeneic bone marrow transplants: a case-control study. Infect. Control 6:347-355.
287. Rousey, S. R., S. Russler, M. Gottlieb, and R. C. Ash. 1991. Low-dose amphotericin B prophylaxis against invasive Aspergillus infections in allogeneic marrow transplantation. Am. J. Med. 91:484-492.
288. Rowe, J. M., N. Ciobanu, J. Ascensao, E. A. Stadtmauer, R. S. Weiner, D. P. Schenkein, P. McGlave, H. M. Lazarus, and the Eastern Cooperative Oncology Group. 1994. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. A report from the Eastern Cooperative Oncology Group (ECOG). Ann. Intern. Med. 120: 143-158.
289. Rozenberg-Arska, M., A. W. Dekker, J. Branger, and J. Verhoef. 1991. A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia. J. Antimicrob. Chemother. 27:369-376.
290. Ruhnke, M., A. Eigler, I. Tennagen, B. Geiseler, E. Engelmann, and M. Trautmann. 1994. Emergence of fluconazole resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. J. Clin. Microbiol. 32:2092-2098.
291. Ruskin, J. D., R. P. Wood, M. R. Bailey, C. K. Whitmore, and B. W. Shaw. 1992. Comparative trial of oral clotrimazole and nystatin for oropharyngeal candidiasis prophylaxis in orthotopic liver transplant patients. Oral Surg. Oral Med. Oral Pathol. 74:567-571.
292. Saag, M. S., G. C. Cloud, J. R. Graybill, J. Sobel, C. Tuazon, B. Wiesinger, L. Riser, B. L. Moskovitz, W. E. Dismukes, and the NIAID Mycoses Study Group. 1995. Comparison of fluconazole vs itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis, abstr. 1218. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
293. Sable, C. A., and G. R. Donowitz. 1994. Infections in bone marrow transplant recipients. Clin. Infect. Dis. 18:273-284.
294. Salmon, S. E., M. J. Cline, J. Schultz, and R. I. Lehrer. 1970. Myeloperoxidase deficiency. Immunologic study of genetic leukocyte defects. N. Engl. J. Med. 282:250-253.
295. Samonis, G., A. Gikas, E. J. Anaissie, G. Vrenzos, S. Maraki, Y. Tselentis, and G. P. Bodey. 1993. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob. Agents Chemother. 37:51-53.
296. Samonis, G., K. Rolston, C. Karl, P. Miller, and G. P. Bodey. 1990. Prophylaxis of oropharyngeal candidiasis with fluconazole. Rev. Infect. Dis. 12(Suppl. 3):S369-S373.
297. Sandford, G. R., W. G. Merz, J. R. Wingard, P. Charache, and R. Saral. 1980. The value of fungal surveillance cultures as predictors of systemic fungal infections. J. Infect. Dis. 142:503-509.
298. Sandven, P., A. Bjorneklett, A. Maeland, and the Norwegian Yeast Study Group. 1993. Susceptibilities of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob. Agents Chemother. 37: 2443-2448.
299. Sanguineti, A., K. Carmichael, and K. Campbell. 1993. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch. Intern. Med. 153:1122-1124.
300. Sarosi, G. A., and P. C. Johnson. 1992. Disseminated histoplasmosis in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 14(Suppl. 1):S60-S67.
301. Schaffner, A., and A. Böhler. 1993. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 36:421-424.
302. Schaffner, A., and P. G. Frick. 1985. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J. Infect. Dis. 151:902-910.
303. Schaffner, A., and M. Schaffner. 1995. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J. Infect. Dis. 172:1035-1041.
304. Schattenberg, A., F. De Vries, T. De Witte, O. Cohen, P. Donnelly, and B. E. De Pauw. 1988. Allogeneic bone marrow transplantation after partial lobectomy for aspergillosis of the lung. Bone Marrow Transplant. 3:509-512.
305. Schmitt, H. J., E. M. Bernard, M. Hauser, and D. Armstrong. 1988. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 32:1676-1679.
306. Scrimgeour, E., and J. D. Anderson. 1985. Ketoconazole prophylaxis in patients with solid tumours receiving aggressive immunosuppressive therapy. An open randomized comparison between 200 mg/d and 400 mg/d doses. S. Afr. Med. J. 67:1044-1045.
307. Serody, J. S., M. R. Mill, F. C. Detterbeck, D. T. Harris, and M. S. Cohen. 1993. Blastomycosis in transplant recipients: report of a case and review. Clin. Infect. Dis. 16:54-58.
308. Sharkey-Mathis, P. K., J. Velez, R. Fetchick, and J. R. Graybill. 1993. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J. Acquired Immune Defic. Syndr. 6:809-819.
309. Shepp, D. H., A. Klosterman, M. S. Siegel, and J. D. Meyers. 1985. Comparative trial of ketoconazole and nystatin for prevention of fungal infection in neutropenic patients treated in a protective environment. J. Infect. Dis. 152:1257-1263.
310. Sherertz, R. J., A. Balani, B. S. Kramer, G. J. Elfenbein, R. S. Weiner, M. L. Sullivan, R. G. Thomas, and G. P. Samsa. 1987. Impact of air filtration on nosocomial Aspergillus infections. Am. J. Med. 83:709-718.
311. 3: demonstration of efficacy in a prospective, multicenter trial. Clin. Infect. Dis. 23:1282-1286.
312. Singh, N., L. Mieles, V. L. Yu, and T. Gayowski. 1993. Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure of prophylaxis with low-dose amphotericin B. Clin. Infect. Dis. 17:906-908.
313. Slavin, M. A., B. Osborne, R. Adams, M. J. Levenstein, H. G. Schoch, A. R. Feldman, J. D. Meyers, and R. A. Bowden. 1995. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis. 171: 1545-1552.
314. Sleijfer, D. T., N. H. Mulder, H. G. de Vries-Hospers, V. Filder, H. O. Nieweg, D. van der Waaij, and H. K. van Saene. 1980. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur. J. Cancer 16:859-869.
315. Smith, D., V. Van de Velde, R. Woestenborghs, and B. G. Gazzard. 1992. The pharmacokinetics of oral itraconazole in AIDS patients. J. Pharm. Pharmacol. 44:618-619.
316. Smith, S. D., R. J. Jackson, C. J. Hannakan, R. M. Wadowsky, A. G. Tzakis, and M. I. Rowe. 1993. Selective decontamination in pediatric liver transplants: a randomized prospective study. Transplantation 55:1306-1309.
317. Snydman, D. R., B. G. Werner, N. N. Dougherty, G. Griffith, R. H. Rubin, J. L. Dienstag, R. H. Rohrer, R. Freeman, R. Jenkins, D. Lewis, S. Hammer, E. O'Rourke, G. F. Grady, K. Fawaz, M. M. Kaplan, M. A. Hoffman, A. T. Katz, M. Doran, and the Boston Center for Liver Transplantation CMVIG Study Group. 1993. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 119:984-991.
318. Snydman, D. R., B. G. Werner, B. Heinze-Lacey, V. P. Bernardi, N. L. Tilney, R. L. Kirkman, E. L. Milford, S. I. Cho, H. L. Bush, Jr., A. S. Levey, T. B. Strom, C. B. Carpenter, R. H. Levey, W. E. Harmon, C. E. Zimmerman, M. E. Shapiro, T. Steiman, F. Lo Gerfo, B. Idelson, G. P. J. Schröter, M. J. Levin, J. McIver, J. Leszczynski, and G. F. Grady. 1987. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317:1049-1054.
319. Steinshamm, S., K. Bergh, and A. Waage. 1993. Effects of stem cell factor and granulocyte colony stimulating factor on granulocyte recovery and Candida albicans infection in granulocytopenic mice. J. Infect. Dis. 168: 1444-1448.
320. Stephan, J. L., V. Vlekova, F. Ledeist, S. Blanche, J. Donadieu, A. Durandy, C. Griscelli, and A. Fischer. 1993. Severe combined immunodeficiency: a retrospective study of clinical presentation and outcome in 117 patients. J. Pediatr. 123:564-572.
321. Stevens, D. A., S. I. Greene, and O. S. Lang. 1991. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex: randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch. Intern. Med. 151:2458-2464.
322. Stewart, A., R. Powles, M. Hewetson, J. Antrum, C. Richardson, and J. Mehta. 1995. Costs of antifungal prophylaxis after bone marrow transplantation. A model comparing oral fluconazole, liposomal amphotericin and oral polyenes as prophylaxis against oropharyngeal candidiasis. Pharmacoeconomics 8:350-361.
323. Strausbaugh, L. J., D. L. Sewell, T. T. Ward, M. A. Pfaller, T. Heitzman, and R. Tjoelker. 1994. High frequency of yeast carriage on hands of hospital personnel. J. Clin. Microbiol. 32:2299-2300.
324. Sugar, A. M. 1995. Agents of mucormycosis and related species, p. 2311-2321. In G. L. Mandell. J. E. Bennett and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, Inc., New York, N.Y.
325. Supparatpinyo, K., C. Kamwan, V. Baosoung, K. E. Nelson, and T. Sirisanthana. 1994. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 344:110-113.
326. Tam, J. Y., K. A. Hamed. K. Blume, and C. G. Prober. 1993. Use of itraconazole in treatment or prevention of invasive aspergillosis in bone marrow transplant recipients, abstr. 813. In Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
327. Thunnissen, P. L., W. Sizoo, and W. D. Hendriks. 1991. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth. J. Med. 39:84-91.
328. Todeschini, G., C. Murari, R. Bonesi, G. Pizzolo, G. Amaddi, A. Ambrosetti, S. Ceru, I. Piacentini, N. Martini, P. Montresor, and G. Perona. 1993. Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 12:614-618.
329. Tollemar, J., K. Hockerstedt, B. G. Ericzon, H. Jalanko, and O. Ringden. 1995. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation 59:45-50.
330. Tollemar, J., O. Ringden, S. Andersson, B. Sundberg, P. Ljungman, and G. Tyden. 1993. Randomized double-blind study of liposomal amphotericin B (AmBisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 12:577-582.
331. Tortorano, A. M., M. A. Viviani, A. Pagano, G. Paone, B. Gridelli, G. Breda, and M. Langer. 1995. Candida colonization in orthotopic liver transplantation: fluconazole versus oral amphotericin B. J. Mycol. Med. 5:21-24.
332. Trapnell, C. B., P. K. Narang, R. Li, and J. P. Lavelle. 1996. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann. Intern. Med. 124:573-576.
333. Tricot, G., E. Joosten, M. A. Boogaerts, J. Vande Pitte, and G. Cauwenbergh. 1987. Ketoconazole vs itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev. Infect. Dis. 9(Suppl. 1):S94-S99.
334. Trigg, M. E., D. E. Morgan, T. L. Burns, R. H. Giller, and C. Peters. 1992. Aspergillosis prevention using intranasally-administered amphotericin (INA), abstr. 1396. In Abstracts of the Annual Meeting of the American Society of Clinical Oncology. American Society of Clinical Oncology, Chicago, Ill.
335. Troy, K. M., and J. Cuttner. 1993. Itraconazole prevents invasive fungal disease in patients with acute leukemia undergoing chemotherapy. Blood 82(Suppl. 1):549a. (Abstract.)
336. Tumbarello, M., N. Bevilacqua, G. Federico, G. Morace, R. Cauda, and E. Tacconelli. 1996. Fluconazole-resistant Candida parapsilosis fungemia in a patient with AIDS. Clin. Infect. Dis. 22:179-180.
337. Tumbarello, M., G. Caldarola, E. Tacconelli, G. Morace, B. Posteraro, R. Cauda, and L. Ortona. 1996. Analysis of the risk factors associated with the emergence of azole-resistant oral candidosis in the course of HIV infection. J. Antimicrob. Chemother. 38:691-699.
338. Turhan, A., J. M. Connors, and P. Klimo. 1987. Ketoconazole versus nystatin as prophylaxis against fungal infection for lymphoma patients receiving chemotherapy. Am. J. Clin. Oncol. 10:355-359.
339. Uzun, O., and E. J. Anaissie. 1995. Antifungal prophylaxis in patients with hematologic malignancies: a reappraisal. Blood 86:2063-2072.
340. Van Delden, C., D. P. Lew, B. Chapuis, P. Rohner, and B. Hirschel. 1995. Antifungal prophylaxis in severely neutropenic patients: how much fluconazole is necessary? Clin. Microbiol. Infect. 1:24-30.
341. Van den Saffele, J. K., and J. R. Boelaert. 1996. Zygomycosis in HIV-positive patients: a review of the literature. Mycoses 39:77-84.
342. Van der Meer, J. W. M., M. Vogels, J. H. A. Curfs, and W. M. C. Eling. 1993. Interleukin-1 as a possible agent for treatment of infection. Eur. J. Clin. Microbiol. Infect. Dis. 12:73-77.
343. Varthalitis, I., and F. Meunier. 1995. Prophylaxis of fungal infections, p. 157-177. In F. Meunier (ed.), Baillière's clinical infectious diseases, vol. 2. Baillière Tindall, London, United Kingdom.
344. Verfaillie, C., D. Weisdorf, R. Haake, M. Hostetter, N. K. Ramsay, and P. McGlave. 1991. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant. 8:177-184.
345. Viviani, M. A., A. M. Tortorano, C. Malaspina, M. Colledan, G. Paone, G. Rossi, G. Bordone, and A. Pagano. 1992. Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. Eur. J. Epidemiol. 8:433-436.
346. Vogler, W. R., L. G. Malcom, and E. F. Winton. 1987. A randomized trial comparing ketoconazole and nystatin prophylactic therapy in neutropenic patients. Cancer Invest. 5:267-273.
347. Vos, A., M. A. Pfaller, R. J. Hollis, J. Rhine-Chalberg, and B. N. Doebbeling. 1995. Investigation of Candida albicans transmission in a surgical intensive care unit cluster by using genomic DNA typing methods. J. Clin. Microbiol. 33:576-580.
348. Vreugdenhil, G., B. J. Van Dijke, J. P. Donnelly, I. R. O. Novakova, J. M. M. Raemaekers, M. A. A. Hoogkamp-Korstanje, M. Koster, and B. E. De Pauw. 1993. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leukemia Lymphoma 11:353-358.
349. Wade, J. C., C. A. de Jongh, K. A. Newman, J. Crowley, P. H. Wiernik, and S. C. Schimpff. 1983. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs nalidixic acid. J. Infect. Dis. 147:624-634.
350. Wade, J. C., S. C. Schimpff, M. T. Hargadon, C. L. Fortner, V. M. Young, and P. H. Wiernic. 1981. A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N. Engl. J. Med. 304:1057-1062.
351. Wade, J. J., N. Rolando, K. Hayllar, J. Philpott-Howard, M. W. Casewell, and R. Williams. 1995. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 21:1328-1336.
352. Wajszczuk, C. P., J. S. Dummer, M. Ho, D. H. Van Thiel, T. E. Starzl, S. Iwatsuki, and B. Shaw, Jr. 1985. Fungal infections in liver transplant recipients. Transplantation 40:347-353.
353. Wakerly, L., A. M. Craig, M. Malek, U. Hoffmeyer, A. Lloyd, F. Valette, R. Phillips, and M. Zabihollah. 1996. Fluconazole versus oral polyenes in the prophylaxis of immunocompromised patients: a cost-minimization analysis. J. Hosp. Infect. 33:35-48.
354. Walsh, T. J., S. Aoki, F. Mechinaud, J. Bacher, J. Lee, M. Rubin, and P. A. Pizzo. 1990. Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis. J. Infect. Dis. 161:755-760.
355. Walsh, T. J., B. De Pauw, E. Anaissie, and P. Martino. 1994. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients. J. Med. Vet. Mycol. 32(Suppl. 1):33-51.
356. Walsh, T. J., C. Gonzalez, E. Roilides, B. U. Mueller, N. Ali, L. L. Lewis, T. O. Whitcomb, D. J. Marshall, and P. A. Pizzo. 1995. Fungemia in children infected with the human immunodeficiency virus: new epidemiologic patterns, emerging pathogens, and improved outcome with antifungal therapy. Clin. Infect. Dis. 20:900-906.
357. Walsh, T. J., and J. W. Lee. 1993. Prevention of invasive fungal infections in patients with neoplastic diseases. Clin. Infect. Dis. 17(Suppl. 2):468-480.
358. Walsh, T. J., K. R. Newman, M. Moody, R. C. Wharton, and J. C. Wade. 1986. Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 65:268-279.
359. Warnock, D. W. 1995. Fungal complications of transplantation: diagnosis, treatment and prevention. J. Antimicrob. Chemother. 36(Suppl. B):73-90.
360. Waser, M., M. Maggiorini, A. Lüthy, A. Laske, L. von Segesser, P. Mohacsi, M. Opravil, M. Turina, F. Follath, and A. Gallino. 1994. Infectious complications in 100 consecutive heart transplant recipients. Eur. J. Clin. Microbiol. Infect. Dis. 13:12-18.
361. Webster, A. D. B. 1994. Infection in primary immunodeficiency syndromes. Curr. Opin. Infect. Dis. 7:444-449.
362. Weems, J. J. Jr. 1992. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin. Infect. Dis. 14:756-766.
363. Weiland, D., R. M. Ferguson, P. K. Peterson, D. C. Snover, R. L. Simmons, and J. S. Najarian. 1983. Aspergillosis in 25 transplant recipients. Ann. Surg. 198:622-629.
364. Wey, S. B. 1993. Nosocomial infection in the compromised host, p. 923-957. In R. P. Wenzel (ed.), Prevention and control of nosocomial infections, 2nd ed. The Williams & Wilkins Co., Baltimore, Md.
365. Wey, S. B., M. Mon, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1989. Risk factors for candidemia. A matched case-control study. Arch. Intern. Med. 149:2349-2353.
366. Wheat, J. 1994. Histoplasmosis and coccidioidomycosis in individuals with AIDS: a clinical review. Infect. Dis. Clin. North Am. 8:467-482.
367. Wheat, J. 1995. Endemic mycoses in AIDS: a clinical review. Clin. Microbiol. Rev. 8:146-159.
368. Wheat, J., and M. Goldman. 1994. Antifungal prophylaxis in AIDS: should it be the standard of care? AIDS Clin. Care 6:27-30.
369. Wheat, J., R. Hafner, M. Wulfsohn, P. Spencer, K. Squires, W. Powderly, B. Wong, M. Rinaldi, M. Saag, K. Hamill, K. Murphy, P. Connolly-Stringfield, N. Briggs, S. Owens, and the NIAID Clinical Trials and Mycoses Study Group collaborators. 1993. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 118:610-616.
370. Wheat, J., H. Vanden Bossche, and P. Marichal. 1996. Mechanism for resistance of Histoplasma capsulatum to fluconazole, abstr. 565. In Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections.
371. Wheat, J. L., P. A. Connolly-Stringfield, R. L. Baker, M. F. Curfman, M. E. Eads, K. S. Israel, S. A. Norris, D. H. Webb, and M. L. Zeckel. 1990. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 69:361-374.
372. Wheat, L., S. Mawhinney, R. Jafner, and D. McKinsey. 1994. Fluconazole treatment for histoplasmosis in AIDS, abstr. 1233. In Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
373. Wheat, L. J. 1993. Diagnosis and management of fungal infections in AIDS. Curr. Opin. Infect. Dis. 6:617-627.
374. Wiesner, R. H. 1990. The incidence of gram-negative bacterial and fungal infections in liver transplant patients treated with selective decontamination. Infection 18(Suppl. 1):S19-S21.
375. Wiley, J. M., N. Smith, B. G. Leventhal, M. L. Graham, L. C. Strauss, C. A. Hurwitz, J. Modlin, D. Mellits, R. Baumgardner, B. J. Corden, and C. I. Civin. 1990. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J. Clin. Oncol. 8:280-286.
376. Williams, C., J. M. Whitehoose, T. A. Lister, and P. F. Wrigley. 1977. Oral anticandidal prophylaxis in patients undergoing chemotherapy for acute leukemia. Med. Pediatr. Oncol. 3:275-280.
377. Wimperis, J. Z., T. P. Baglin, R. E. Marcus, and R. E. Warren. 1991. An assessment of the efficacy of antimicrobial prophylaxis in bone marrow autografts. Bone Marrow Transplant. 8:363-367.
378. Wingard, J. R. 1992. The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. Leukemia Lymphoma 8:353-359.
379. Wingard, J. R. 1994. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. 19(Suppl. 1):S49-S53.
380. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1247.
381. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
382. Wingard, J. R., W. P. Vaughan, H. G. Braine, W. G. Merz, and R. Saral. 1987. Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. Am. J. Med. 83:1103-1110.
383. Winston, D. J., P. H. Chandrasekar, H. M. Lazarus, J. L. Goodman, J. L. Silber, H. Horowitz, R. K. Shadduck, C. S. Rosenfeld, W. G. Ho, M. Z. Islam, and D. N. Buell. 1993. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann. Intern. Med. 118:495-503.
384. Winston, D. J., C. Emmanouilides, and R. W. Busuttil. 1995. Infections in liver transplanted recipients. Clin. Infect. Dis. 21:1077-1091.
385. Wolf, S., J. Fay, D. Stevens, R. Herzig, B. Bolwell, J. Lynch, C. Freytes, F. LeMaistre, R. Collins, L. Pineiro, J. Greer, R. Stein, S. Goodman, K. Rogers, and S. Dummer. 1993. Fluconazole versus low dose amphotericin B for the prevention of fungal infections in patients undergoing marrow transplantation. A study of the North American Bone Marrow Transplant Group (NAMTG). Blood 82(Suppl. 1):25a. (Abstract.)
386. Working Party of the British Society for Antimicrobial Chemotherapy. 1993. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. Working Party report. J. Antimicrob. Chemother. 32:5-21.
387. Yamaç, K., E. Senol, and R. Haznedar. 1995. Prophylactic use of fluconazole in neutropenic cancer patients. Postgrad. Med. J. 71:284-286.
388. Yamada, T., K. Dan, and T. Nomura. 1993. Prevention of bacterial and fungal infections in acute leukemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Intern. Med. 32:710-715.
389. Veo, E., T. Alvarado, V. Fainstein, and G. P. Bodey. 1985. Prophylaxis of oropharyngeal candidiasis with clotrimazole. J. Clin. Oncol. 3:1668-1671.
390. Zar, F. A., and M. Fernandez. 1991. Failure of ketoconazole maintenance therapy for disseminated coccidioidomycosis in AIDS. J. Infect. Dis. 164: 824-825.